Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis

Saleem, Kainat; Franz, Joseph; Klem, Mary Lou; Yabes, Jonathan G.; Boyiadzis, Michael; Jones, J.; Shaikh, Nader; Lontos, Konstantinos

doi:10.1016/s2352-3026(22)00289-7

Cited by 18 publications

(8 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the pathogenesis of SPM is unclear, the use of alkylating agents, biological factors, genetic predisposition, and immune dysfunctions are a possible mechanism for the development of SPM in patients with MM [ 1 , 19 ]. Further, growing evidence has revealed that the use of lenalidomide is associated with an increased risk of SPM in MM [ 20 ]. Increased surveillance and genetic polymorphisms can explain the increased risk of SPM [ 20 , 21 ].…”

Section: Discussionmentioning

confidence: 99%

“…Further, growing evidence has revealed that the use of lenalidomide is associated with an increased risk of SPM in MM [ 20 ]. Increased surveillance and genetic polymorphisms can explain the increased risk of SPM [ 20 , 21 ]. Lenalidomide is associated with an increased risk of SPM in patients with MM, with a risk ratio of 1.30 [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

“…Increased surveillance and genetic polymorphisms can explain the increased risk of SPM [ 20 , 21 ]. Lenalidomide is associated with an increased risk of SPM in patients with MM, with a risk ratio of 1.30 [ 20 ]. The incidence of SPM ranges from 6.9% to 18.9% [ 20 , 22 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report

Tamai,

Hirose,

Akazawa

et al. 2024

surg case rep

View full text Add to dashboard Cite

Background Concomitant multiple myeloma (MM) and other primary malignancies is rare. Therefore, the treatment outcomes of patients with these conditions have not been well discussed. Lenalidomide is an oral thalidomide analog drug used for MM. Recently, the antitumor effect of lenalidomide has been gaining attention, and lenalidomide has been applied for managing solid tumors. The current case showed the treatment course of a patient treated with lenalidomide for concomitant MM and colon cancer with peritoneal dissemination. Case presentation A 74-year-old female patient receiving treatment for MM was diagnosed with mucinous adenocarcinoma of the transverse colon. The patient was clinically diagnosed with stage IIIC T4aN2M0 disease. Subsequently, laparoscopic colectomy with lymph node dissection was planned. However, intraperitoneal observation revealed peritoneal dissemination that had sporadically and widely spread. Therefore, palliative partial colectomy was performed to prevent future hemorrhage or obstruction. The patient was discharged on the 10th postoperative day without postoperative complication. Based on the patient’s preference, lenalidomide was continually administered for MM without systemic chemotherapy. The patient survived for > 36 months without any signs of tumor progression. Conclusion The current case first showed the treatment course of concomitant MM and colon cancer. The antitumor effect of lenalidomide can possibly contribute to 3-year progression-free survival in patients with mucinous adenocarcinoma of the colon with peritoneal dissemination.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report

Tamai,

Hirose,

Akazawa

et al. 2024

surg case rep

View full text Add to dashboard Cite

show abstract

“…A recent meta‐analysis evaluated the risk of SPM in patients receiving Len for various malignancies 17 . An increased risk ratio for developing SPM with Len treatment was observed only in patients who received this agent for MM (RR 1·42, 95% Confidence Interval 1.09–1.84).…”

Section: Discussionmentioning

confidence: 99%

“…A recent meta-analysis evaluated the risk of SPM in patients receiving Len for various malignancies. 17 An increased risk ratio for developing SPM with Len treatment was observed only in patients who received this agent for MM (RR 1Á42, 95% Confidence Interval 1.09-1.84). In the present study we found that a longer duration of Len maintenance was associated with a higher odds of developing SPM, reaching statistical significance after 2 years.…”

Section: Joseph Et Al Described Outcomes Of 1000 MM Patients Treatedmentioning

confidence: 98%

Single‐agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience

et al. 2023

View full text Add to dashboard Cite

The optimal duration of lenalidomide (Len) maintenance for patients with multiple myeloma (MM) after autologous stem cell transplantation (autoHCT) is unknown. We conducted a retrospective single‐center analysis of adult MM patients that received upfront autoHCT between 2005 and 2021, followed by single‐agent Len maintenance. A total of 1167 patients were included with a median age of 61.4 (range 25.4–82.3) years, and high‐risk chromosomal abnormalities in 19%. Median duration of maintenance was 22.3 (range 0.03–139.6) months. After a median follow‐up of 47.9 (range 2.9–171.7) months, median PFS and OS for the entire cohort were 56.6 (95% CI 48.2–61.4) months and 111.3 (95% CI 101.7–121.5) months, respectively. In MVA, high‐risk cytogenetics was associated with a worse PFS (HR 1.91) and OS (HR 1.73) (p < .001 for both). Use of KRD induction and achievement of MRD‐negative ≥ VGPR before autoHCT were associated with an improved PFS (HR 0.53 and HR 0.57, respectively; p < .001 for both). Longer maintenance duration, even with a 5‐year cutoff, was associated with superior PFS and OS (HR 0.17 and 0.12, respectively; p < .001 for both). A total of 106 patients (9%) developed a second primary malignancy (SPM), mostly solid tumors (39%) and myeloid malignancies (30%). Longer maintenance duration was associated with a higher risk of SPM, reaching statistical significance after >2 years (odds ratio 2.25; p < .001). In conclusion, outcomes with Len maintenance were comparable to those reported in large clinical trials. Longer duration of maintenance, even beyond 5 years, was associated with improved survival.

show abstract

‘Secondary’ acute lymphoblastic/lymphocytic leukemia - done playing second fiddle?

2023

View full text Add to dashboard Cite

Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis

Cited by 18 publications

References 77 publications

Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report

Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report

Single‐agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience

‘Secondary’ acute lymphoblastic/lymphocytic leukemia - done playing second fiddle?

Contact Info

Product

Resources

About